Tarpgaard et al is: Repurposing of Drugs in Chemotherapy Resistant Colorectal Cancer

Line Tarpgaard, SofieOtzen Bagger, Per Pfeiffer, Nils Brünner and Jan Stenvang2*

Department of Oncology, Odense University Hospital, Denmark
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark

^*Correspondance to: Jan Stenvang 

 PDF  Full Text Mini Review | Open Access

Abstract:

Chemotherapy resistance remains a major clinical problem in the current treatment of cancer patients and chemotherapy resistance almost inevitably occursin metastatic cancer patients.In colorectal cancer patients, the response rates to first line chemotherapy therapy is approximately 50%, dropping to approximately 10-20% in second line treatment and no standard third line treatment exists. Thus, there is an obvious and acute need for novel drugs to increase response rates. Here, we focus on the promising idea of repurposing existing drugs in clinical trials with chemotherapy resistant colorectal cancer patients and suggest a general clinical trial design that could be employed to test repurposed drugs.

Keywords:

Cite the Article:

Tarpgaard L, Bagger SO, Pfeiffer P, Brünner N, Stenvang J. Tarpgaard et al is: Repurposing of Drugs in Chemotherapy Resistant Colorectal Cancer. Clin Oncol. 2017; 2: 1382.